An international research team led by Prof. Dr. Sedat Nizamoğlu from the Department of Electrical and Electronics Engineering ...

New research finds that retinal diseases thought to map one-to-one to genetic mutations are more complicated than that.

Population-based studies have shown retinal disorders are the most common cause of irreversible blindness in developed countries and the second most common cause of blindness after cataracts in ...

The study showed that nanoparticles injected into the retina can successfully stimulate the visual system and restore vision in mice with retinal diseases. The findings suggest that a new type of ...

Dr Sunir Garg reflects on the recent American Academy of Ophthalmology meeting in Orlando and expresses excitement on how artificial intelligence (AI) can be used to detect, treat, and transform the ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...

The Korea Research Institute of Standards and Science (KRISS) has developed a retina-mimicking eye phantom that faithfully replicates the structural layers and microvascular network of the human ...

Golgi Neurosciences srl and Breye Therapeutics ApS have established a collaboration to develop Golgi’s P2X7 receptor antagonist program for retinal disorders. The companies have now closed the ...

Sunir Garg, MD, expresses excitement about attending AAO 2025 and focuses on several topics to be discussed. These include the benefits and potential vision risks of GLP-1 inhibitors in patients with ...

A one-time treatment with Luxturna, the first US Food and Drug Administration-approved gene therapy for an inherited disorder, will cost $425,000 per eye. A one-time treatment with Luxturna, the first ...